Article
Gastroenterology & Hepatology
Maria Chaparro, Ana Garre, Francisco Mesonero, Cristina Rodriguez, Manuel Barreiro-de Acosta, Jesus Martinez-Cadilla, Maria T. Arroyo, Noemi Mancenido, Monica Sierra-Ausin, Isabel Vera-Mendoza, Maria Jose Casanova, Pilar Nos, Carlos Gonzalez-Munoza, Teresa Martinez, Maia Bosca-Watts, Margalida Calafat, David Busquets, Eva Girona, Jordina Llao, Maria Dolores Martin-Arranz, Marta Piqueras, Laura Ramos, Gerard Suris, Fernando Bermejo, Ana Y. Carbajo, Diego Casas-Deza, Agnes Fernandez-Clotet, Maria J. Garcia, Daniel Ginard, Ana Gutierrez-Casbas, Luis Hernandez, Alfredo J. Lucendo, Lucia Marquez, Olga Merino-Ochoa, Francisco J. Rancel, Carlos Taxonera, Antonio Lopez Sanroman, Saioa Rubio, Eugeni Domenech, Javier P. Gisbert
Summary: The study findings indicate that tofacitinib is effective and safe in treating active ulcerative colitis. However, a significant proportion of patients discontinue the drug over time, mainly due to primary failure.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Biochemistry & Molecular Biology
Jose M. Huguet, Victor Garcia-Lorenzo, Lidia Marti, Jose Maria Paredes, Jose Joaquin Ramirez, Miguel Pastor, Lucia Ruiz, Ana Sanahuja, Pilar Timoneda, Laura Sanchis, Gloria Alemany Perez, Marta Maia Bosca-Watts
Summary: This study evaluated the efficacy and safety of subcutaneous infliximab in patients with inflammatory bowel disease. The results showed that subcutaneous administration of infliximab has the potential to maintain treatment stability and increase drug levels. This is of great significance for the management of patients with inflammatory bowel disease.
Article
Gastroenterology & Hepatology
Maria Chaparro, Ana Garre, Marisa Iborra, Monica Sierra-Ausin, Manuel Barreiro-de Acosta, Agnes Fernandez-Clotet, Luisa de Castro, Maia Bosca-Watts, Maria Jose Casanova, Alicia Lopez-Garcia, Rufo Lorente, Cristina Rodriguez, Ana Y. Carbajo, Maria Teresa Arroyo, Ana Gutierrez, Joaquin Hinojosa, Teresa Martinez-Perez, Albert Villoria, Fernando Bermejo, David Busquets, Blau Camps, Fiorella Canete, Noemi Mancenido, David Monfort, Merce Navarro-Llavat, Jose Lazaro Perez-Calle, Laura Ramos, Montserrat Rivero, Teresa Angueira, Patricia Camo Monterde, Daniel Carpio, Irene Garcia-de-la-Filia, Carlos Gonzalez-Munoza, Luis Hernandez, Jose M. Huguet, Victor J. Morales, Beatriz Sicilia, Pablo Vega, Isabel Vera, Yamile Zabana, Pilar Nos, Patricia Suarez Alvarez, Cristina Calvino-Suarez, Elena Ricart, Vicent Hernandez, Miguel Minguez, Lucia Marquez, Daniel Hervias Cruz, Saioa Rubio Iturria, Jesus Barrio, Carla Gargallo-Puyuelo, Ruben Frances, Esther Hinojosa, Maria del Moral, Xavier Calvet, Alicia Algaba, Xavier Aldeguer, Jordi Guardiola, Miriam Manosa, Ramon Pajares, Marta Piqueras, Orlando Garcia-Bosch, Pilar Lopez Serrano, Beatriz Castro, Alfredo J. Lucendo, Miguel Montoro, Elena Castro Ortiz, Francisco Mesonero, Esther Garcia-Planella, David A. Fuentes, Inmaculada Bort, Pedro Delgado-Guillena, Lara Arias, Agueda Iglesias, Marta Calvo, Maria Esteve, Eugeni Domenech, Javier P. Gisbert
Summary: Ustekinumab has shown durability and effectiveness in the treatment of ulcerative colitis, even in real life situations. Higher levels of serum C-reactive protein were associated with a lower probability of achieving remission. In the short term, 53% of patients showed a positive response to the treatment.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
Wei-Chen Lin, Wei-Chen Tai, Chung-Hsin Chang, Chia-Hung Tu, I-Che Feng, Ming-Jium Shieh, Chen-Shuan Chung, Hsu-Heng Yen, Jen-Wei Chou, Jau-Min Wong, Yu-Hwa Liu, Tien-Yu Huang, Chiao-Hsiung Chuang, Tzung-Jiun Tsai, Feng-Fan Chiang, Chien-Yu Lu, Wen-Hung Hsu, Fang-Jung Yu, Te-Hsin Chao, Deng-Chyang Wu, Ai-Sheng Ho, Hung-Hsin Lin, Chun-Lung Feng, Keng-Liang Wu, Ming-Wun Wong, Chien-Chih Tung, Chun-Chi Lin, Chia-Chang Chen, Huang-Ming Hu, Lung-Sheng Lu, Huann-Sheng Wang, I-Chen Wu, Hsin-Yu Kuo, Jia-Feng Wu, Hsiang Yao Shih, Yen-Hsuan Ni, Shu-Lun Tang, Peng-Hsu Chen, Shu-Chen Wei
Summary: This nationwide prospective registry study investigated the real-world effectiveness, safety, and persistence of vedolizumab (VDZ) in inflammatory bowel disease (IBD) patients in Taiwan. Disease relapse rates after VDZ discontinuation due to reimbursement restriction were assessed.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Maria Chaparro, Diana Acosta, Cristina Rodriguez, Francisco Mesonero, Miren Vicuna, Manuel Barreiro-de Acosta, Agnes Fernandez-Clotet, Alvaro Hernandez Martinez, Maite Arroyo, Isabel Vera, Alexandra Ruiz-Cerulla, Beatriz Sicilia, M. Jose Cabello Tapia, Carmen Munoz Villafranca, Jesus Castro-Poceiro, Jesus Martinez Cadilla, Monica Sierra-Ausin, Juan Maria Vazquez Moron, Raquel Vicente Lidon, Fernando Bermejo, Vanesa Royo, Margalida Calafat, Carlos Gonzalez-Munoza, Eduardo Leo Carnerero, Noemi Mancenido Marcos, Leyanira Torrealba, Horacio Alonso-Galan, Jose Manuel Benitez, Yolanda Ber Nieto, M. Teresa Diz-Lois Palomares, Maria Jose Garcia, Jose Fernando Munoz, Edisa Maria Armesto Gonzalez, Xavier Calvet, Alejandro Hernandez-Camba, Rosa Eva Madrigal Dominguez, Luis Menchen, Jose Lazaro Perez Calle, Marta Piqueras, Carmen Duenas Sadornil, Belen Botella, Teresa de Jesus Martinez-Perez, Laura Ramos, Maria Carmen Rodriguez-Grau, Elena San Miguel, Jose Luis Fernandez Forcelledo, Paola Maria Fradejas Salazar, Marife Garcia-Sepulcre, Ana Gutierrez, Jordina Llao, Eva Sese Abizanda, Maia Bosca-Watts, Eduardo Iyo, Alma Keco-Huerga, Carmen Martinez Bonil, Elena Pena Gonzalez, Pablo Perez-Galindo, Pilar P. Varela, Javier Gisbert, To ReWard Study Grp
Summary: This study aims to evaluate the durability, short-term and long-term effectiveness, and safety of tofacitinib in ulcerative colitis (UC) in clinical practice. The study found that tofacitinib is effective in both short-term and long-term treatment of UC patients, and its safety profile is consistent with previous reports.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Tessa Straatmijer, Fiona D. M. van Schaik, Alexander G. L. Bodelier, Marijn Visschedijk, Annemarie C. de Vries, Cyriel Y. Ponsioen, Marieke Pierik, Ad A. van Bodegraven, Rachel L. West, Nanne K. H. de Boer, Nidhi Srivastava, Tessa E. H. Romkens, Jildou Hoekstra, Bas Oldenburg, Gerard Dijkstra, Janneke C. van der Woude, Mark Lowenberg, Zlatan Mujagic, Vince B. C. Biemans, Andrea E. Van der Meulen-de Jong, Marjolijn Duijvestein
Summary: The aim of this study was to evaluate the effectiveness and safety of 24 months of tofacitinib use in patients with ulcerative colitis in the Netherlands. The results showed that 31.8% of patients achieved corticosteroid-free clinical remission after 24 months of tofacitinib treatment. The main side effects were skin reactions and headaches.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Carlos Taxonera, David Olivares, Olga N. N. Lopez-Garcia, Cristina Alba
Summary: This study provides evidence on the real-world outcomes of ustekinumab for ulcerative colitis (UC) patients. The meta-analysis confirms the effectiveness of ustekinumab in achieving clinical remission and response in a highly treatment-refractory population of UC patients. The safety profile of ustekinumab is also demonstrated with low rates of adverse events and serious infections.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Makoto Naganuma, Taku Kobayashi, Reiko Kunisaki, Katsuyoshi Matsuoka, Shojiro Yamamoto, Ami Kawamoto, Daisuke Saito, Kosaku Nanki, Kazuyuki Narimatsu, Hisashi Shiga, Motohiro Esaki, Shinichiro Yoshioka, Shingo Kato, Masayuki Saruta, Shinji Tanaka, Eriko Yasutomi, Kaoru Yokoyama, Kei Moriya, Yoshikazu Tsuzuki, Makoto Ooi, Mikihiro Fujiya, Atsushi Nakazawa, Takayuki Abe, Tadakazu Hisamatsu, Japanese UC Study Grp
Summary: Most first-use advanced therapies were effective for patients with acute severe ulcerative colitis, while second-use advanced therapies might have had limited benefits in inducing clinical remission. These findings may provide insights for the management of hospitalized patients.
JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Pharmacology & Pharmacy
Kaituo Huang, Jing Liu, Wenhao Xia, Chuwen Tian, Lingya Yao, Qian Cao, Haotian Chen
Summary: This study evaluated the long-term effectiveness and safety of vedolizumab (VDZ) in Chinese patients with ulcerative colitis (UC). The results showed favorable outcomes in terms of clinical response, clinical remission, and steroid-free clinical remission at both the 14-week and 52-week time points. The most common adverse event during the follow-up period was skin rash, and no new safety signals were found. Overall, the results of this study were similar to previous studies in other geographical regions and populations.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Rheumatology
Yusuke Miyazaki, Masashi Funada, Shingo Nakayamada, Koshiro Sonomoto, Hiroaki Tanaka, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Ayako Yamaguchi, Ippei Miyagawa, Yasuyuki Todoroki, Masanobu Ueno, Yoshiya Tanaka
Summary: This retrospective observational study found that anifrolumab is both safe and effective in treating patients with systemic lupus erythematosus. It can effectively reduce disease activity and reduce the need for glucocorticoid use.
Article
Gastroenterology & Hepatology
Ryusuke Nambu, Takahiro Kudo, Nao Tachibana, Hirotaka Shimizu, Tatsuki Mizuochi, Sawako Kato, Mikihiro Inoue, Hideki Kumagai, Takashi Ishige, Reiko Kunisaki, Atsuko Noguchi, Toshifumi Yodoshi, Shin-Ichiro Hagiwara, Shigeo Nishimata, Fumihiko Kakuta, Takeshi Saito, Itaru Iwama, Yuri Hirano, Toshiaki Shimizu, Katsuhiro Arai
Summary: In pediatric UC patients, approximately 50% underwent colectomy during a 2-year interval following IFX failure. Prognosis after IFX failure appeared to improve with availability of new biologic agents and small-molecule drugs in mid-2018.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Pharmacology & Pharmacy
Fang Wang, Xiaofei Li, Yanting Shi, He Zhou, Gang Yang, Ruixia Li, Tong Wu, Jie Liang
Summary: This study found that the ADA biosimilar HS016 had good efficacy and safety in Chinese IBD patients. The majority of Crohn's disease and ulcerative colitis patients achieved clinical response and remission after treatment with HS016.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Gastroenterology & Hepatology
Irit Avni-Biron, Ariella Bar-Gil Shitrit, Benjamin Koslowsky, Asaf Levartovsky, Uri Kopylov, Roni Weisshof, Nathaniel Aviv Cohen, Nitsan Maharshak, David Hovel, Eran Israeli, Timna Naftali, Idan Goren, Yfat Snir, Jacob E. Ollech, Hagar Banai-Eran, Yelena Broitman, Tali Sharar-Fischler, Iris Dotan, Henit Yanai
Summary: Tofacitinib showed effectiveness and safety in treating moderate to severe ulcerative colitis in Israeli patients, achieving corticosteroid-free remission in about 20% of patients with extensive biologics experience. Despite some patients continuing to use tofacitinib at 26 weeks, it was well tolerated and safe. Earlier use of tofacitinib in the treatment algorithm may lead to improved outcomes.
DIGESTIVE AND LIVER DISEASE
(2022)
Article
Medicine, General & Internal
Jose Maria Huguet, Xavier Cortes, Marta Maia Bosca-Watts, Marian Aguas, Nuria Maroto, Lidia Marti, Cirilo Amoros, Jose Maria Paredes
Summary: This study analyzed clinical response rates and adverse events in IBD patients treated with CT-P13 in real-life practice. The results showed that CT-P13 is an effective and safe infliximab biosimilar for the treatment of IBD, with sustained clinical remission and response rates over 12 months.
WORLD JOURNAL OF CLINICAL CASES
(2021)
Article
Biotechnology & Applied Microbiology
Bernd Bokemeyer, Tibor Hlavaty, Matthieu Allez, Pamela Selema, Shahrzad Moosavi, Mary Jane Cadatal, Heather Fowler, Markus Mueller, Katherine F. Liau, Javier P. Gisbert
Summary: This study investigated the use of CT-P13 in the treatment of patients with Crohn's disease and ulcerative colitis. The results showed that the safety information for CT-P13 was consistent with the known safety profile for IFX and did not alter the established benefit-risk profile of CT-P13.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)